A multicenter phase-II study of 5-FU, leucovorin and oxaliplatin (FOLFOX6) in patients with pretreated metastatic colorectal cancer

Japanese Journal of Clinical Oncology

Volumn 41, Issue 1, 2011, Pages 63-68

  Kato, Ken ^a   Inaba, Yoshitaka ^b   Tsuji, Yasushi ^c   Esaki, Taito ^d   Yoshioka, Akira ^e   Mizunuma, Nobuyuki ^f   Mizuno, Toshiro ^g   Kusaba, Hitoshi ^h   Fujii, Hirohumi ⁱ   Muro, Kei ^a,b   Shimada, Yasuhiro ^a   Shirao, Kuniaki ^j  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c Tonan Hospital   (Japan)

^d NATIONAL KYUSHU CANCER CENTER   (Japan)

^e MITSUBISHI KYOTO HOSPITAL   (Japan)

^f CANCER INSTITUTE HOSPITAL   (Japan)

^g MIE UNIVERSITY HOSPITAL   (Japan)

^h KYUSHU UNIVERSITY   (Japan)

ⁱ JICHI MEDICAL UNIVERSITY   (Japan)

^j OITA UNIVERSITY HOSPITAL   (Japan)

more..

Author keywords

Colorectal cancer; FOLFOX6; Second line

Indexed keywords

FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CHEMOTHERAPY INDUCED EMESIS; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; JAPANESE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PIGMENTATION; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; JAPAN; LEUCOVORIN; MALE; MIDDLE AGED; NEUTROPENIA; ORGANOPLATINUM COMPOUNDS; PERIPHERAL NERVOUS SYSTEM DISEASES; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 78650776256     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyq158     Document Type: Article

References (20)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. American Cancer Society, Cancer Statistics 2004. CA Cancer J Clin 2004;54:8-29.
2. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533-43.
3. Cancer Statistics in Japan Editorial Board. Cancer Statistics in Japan 2008. Foundation for Promotion of Cancer Research. 2008 (in Japanese).
4. Tsukuma H, Ajiki W, Ioka A, Oshima A. Research Group of Population-Based Cancer Registries of Japan. Survival of cancer patients diagnosed between 1993 and 1996: a collaborative study of population-based cancer registries in Japan. Jpn J Clin Oncol 2006;36:602-7.
5. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, et al. Superiority of oxaliplatin and fluorouracilleucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003;21:2059-69.
6. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
7. Rougier P, Lepille D, Bennouna J, Marre A, Ducreux M, Mignot L, et al. Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study. Ann Oncol 2002;13:1558-67.
8. Maindrault-Goebel F, Louvet C, André T, Carola E, Lotz JP, Molitor JL, et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer 1999;35:1338-42.
9. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-37.
10. Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
11. National Cancer Institute-Common Toxicity Criteria. (NCI-CTC Version 3.0, March 31, 2003).
12. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-44.
13. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009;27:3677-83.
14. Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol 2006;24:394-400.
15. Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008;26:3523-9.
16. Shimizu T, Satoh T, Tamura K, Ozaki T, Okamoto I, Fukuoka M, et al. Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience. Int J Clin Oncol. 2007;12:218-23.
17. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013-9.
18. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360:1408-17.
19. Kozloff M, Yood MU, Berlin J, Flynn PJ, Kabbinavar FF, Purdie DM, et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 2009;14:862-70.
20. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65.